A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

March 12, 2025

Study Completion Date

May 31, 2040

Conditions

Osteosarcoma

Interventions

BIOLOGICAL

SCRI-E2CAR_EGFRtv1

Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)

DRUG

UB_TT170

Bispecific small molecule adapter formulated with phosphate buffered saline

Trial Locations (1)

Seattle Children's Hospital, Seattle

All Listed Sponsors

collaborator

Umoja BioPharma, Inc.

UNKNOWN

lead

Seattle Children's Hospital

OTHER